Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Terminated 1Completed 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 2

Conditions

Stomach Neoplasms 20Carcinoma, Non-Small-Cell Lung 18Neoplasms 10Adenocarcinoma 8Neoplasm Metastasis 7Colorectal Neoplasms 7Carcinoma, Hepatocellular 6Esophageal Neoplasms 5Carcinoma, Renal Cell 5Breast Neoplasms 5Colonic Neoplasms 4Urinary Bladder Neoplasms 3Urethral Neoplasms 3Melanoma 3Liver Neoplasms 3Biliary Tract Neoplasms 3Ureteral Neoplasms 2Solid Tumors 2Sarcoma 2Rectal Neoplasms 2Ovarian Neoplasms 2Non-small Cell Lung Cancer Metastatic 2Malignant Solid Tumor 2Lung Neoplasms 2Fallopian Tube Neoplasms 2Carcinoma, Transitional Cell 2Solid Tumor 1Solid Cancer 1Sarcoma, Synovial 1Sarcoma, Alveolar Soft Part 1

Interventions

tusamitamab ravtansine 2Ramucirumab 2Docetaxel 2telomerase reverse transcriptase p572Y, human 1pembrolizumab 1necitumumab 1Paclitaxel 1LY3023414 1Gemcitabine 1Erlotinib Hydrochloride 1Data Collection 1Carboplatin 1Bevacizumab 11-(1-(imidazo(1,2-a)pyridin-6-yl)ethyl)-6-(1-methyl-1H-pyrazol-4-yl)-1H-(1,2,3)triazolo(4,5-b)pyrazine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
INDUSTRY × Non-small Cell Lung Cancer Metastatic × Ramucirumab × Clear all
NCT04394624 2025-06-06

CARMEN-LC04

Sanofi

Phase 2 Terminated
31 enrolled 22 charts
Thoracic

Non-small Cell Lung Cancer Metastatic

NCT01703091 2019-09-30

A Study of Docetaxel and Ramucirumab Versus Docetaxel and Placebo in the Treatment of Stage IV Non-Small Cell Lung Cancer

Eli Lilly and Company

Phase 2 Completed
197 enrolled 12 charts
Thoracic

Non-small Cell Lung Cancer Metastatic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡